Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.50 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269680 | 0.88 | PDE10A (0.47) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 | |
| SCHEMBL2913941 | 0.87 | PDE10A (0.61) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 | |
| SCHEMBL9479707 | 0.86 | PDE10A (0.46) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 | |
| SCHEMBL9480330 | 0.85 | PDE10A (0.45) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 | |
| SCHEMBL16289622 | 0.85 | PDE10A (0.45) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 | |
| SCHEMBL16287758 | 0.85 | PDE10A (0.45) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 | |
| SCHEMBL6798820 | 0.83 | CYSLTR2 (0.53) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 | |
| SCHEMBL267839 | 0.83 | CYSLTR1 (0.53) | PDE10ACYP1A2CYSLTR2CYSLTR1KDM1A | |
| SCHEMBL2334595 | 0.81 | CYSLTR2 (0.52) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 | |
| SCHEMBL296473 | 0.79 | PDE10A (0.50) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 447 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100415736-C | Quinolylpropylpiperidine derivatives and their use as antimicrobial agents | AVENTIS PHARMA SA (FR) | 2008-09-03 | — | — | CN | claimed |
| CN-1681801-A | Quinolylpropylpiperidine derivatives and their use as antimicrobial agents | AVENTIS PHARMA SA (FR) | 2005-10-12 | — | — | CN | claimed |
| CN-1374959-A | Piperidine quinolyl propyl derivatives, preparation method and compositions containing same | AVENTIS PHARMA SA (FR) | 2002-10-16 | — | — | CN | claimed |
| US-20010036942-A1 | N-oxides of heterocyclic esters, amides, thioesters, and ketones | GLIAMED, INC. | 2001-11-01 | — | — | US | claimed |
| EP-1082095-A1 | N-OXIDE OF HETEROCYCLIC ESTER, AMIDE, THIOESTER OR KETONE HAIR GROWTH COMPOSITIONS AND USES | GPI NIL Holdings, Inc. (US) | 2001-03-14 | — | — | EP | claimed |
| WO-1999062486-A1 | N-OXIDE OF HETEROCYCLIC ESTER, AMIDE, THIOESTER, OR KETONE HAIR GROWTH COMPOSITIONS AND USES | GPI NIL HOLDINGS INC. (US) | 1999-12-09 | — | — | WO | claimed |
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-07-18 | — | — | US | disclosed |
| EP-4375280-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-05-29 | — | — | EP | disclosed |
| EP-4371985-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-05-22 | — | — | EP | disclosed |
| EP-4371984-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-05-22 | — | — | EP | disclosed |
| CN-117881673-A | Synthesis method of bilirubin | 株式会社毕丽斯 | 2024-04-12 | — | — | CN | disclosed |
| CN-117836290-A | Synthesis method of bilirubin | 株式会社毕丽斯 | 2024-04-05 | — | — | CN | disclosed |
| CN-117813301-A | Synthesis method of bilirubin | 株式会社毕丽斯 | 2024-04-02 | — | — | CN | disclosed |
| EP-0678514-A1 | 3,5-Disubstituted tetrahydrofuran-2-ones | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
| US-5449785-A | Fungicides with triazole groups | HOFFMANN-LA ROCHE INC. (US) | 1995-09-12 | — | — | US | disclosed |
| EP-0247381-B1 | 5-FLUROROURACIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-04 | — | — | EP | disclosed |
| CN-1069976-A | Hexanaphthene and tetrahydropyran derivatives | HOFFMANN LA ROCHE (CH) | 1993-03-17 | — | — | CN | disclosed |
| EP-0524439-A1 | Novel cyclohexane and tetrahydropyran derivatives and antifungal compositions containing these derivatives | F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) | 1993-01-27 | — | — | EP | disclosed |
| US-5047521-A | Anticarcinogenic agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| EP-0247381-A2 | 5-flurorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036942-A1 | N-oxides of heterocyclic esters, amides, thioesters, and ketones | FKBP8, FKBP14, FKBP1A | PDE10A 4430/4885CYP1A2 2796/4885CYSLTR2 3523/4885 |
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | CYP7A1, UGT1A3, UGT1A1 | PDE10A 4726/4885CYP1A2 21/4885CYSLTR2 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.